Dicot Pharma AB (STO:DICOT)
Sweden flag Sweden · Delayed Price · Currency is SEK
0.3400
-0.0045 (-1.31%)
At close: May 9, 2025

Dicot Pharma AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Selling, General & Admin
68.9659.0645.0331.6727.1317.52
Upgrade
Other Operating Expenses
0.210.21-00.130.110.04
Upgrade
Operating Expenses
69.1859.2845.0331.827.2517.56
Upgrade
Operating Income
-69.18-59.28-45.03-31.8-27.25-17.56
Upgrade
Interest Expense
-0.01-0.01-0.07-0.03-0-0.01
Upgrade
Interest & Investment Income
2.171.570.91-00.01
Upgrade
Currency Exchange Gain (Loss)
0.030.030.030.080.050.02
Upgrade
EBT Excluding Unusual Items
-67-57.7-44.16-31.76-27.2-17.54
Upgrade
Gain (Loss) on Sale of Assets
----0.03-
Upgrade
Pretax Income
-67-57.7-44.16-31.76-27.17-17.54
Upgrade
Net Income
-67-57.7-44.16-31.76-27.17-17.54
Upgrade
Net Income to Common
-67-57.7-44.16-31.76-27.17-17.54
Upgrade
Shares Outstanding (Basic)
1,3311,0915301206429
Upgrade
Shares Outstanding (Diluted)
1,3311,0915301216429
Upgrade
Shares Change (YoY)
102.30%105.97%336.53%89.21%124.32%187.81%
Upgrade
EPS (Basic)
-0.05-0.05-0.08-0.26-0.42-0.61
Upgrade
EPS (Diluted)
-0.05-0.05-0.08-0.26-0.42-0.61
Upgrade
Free Cash Flow
-63.77-58.87-45.23-29.71-25.87-16.29
Upgrade
Free Cash Flow Per Share
-0.05-0.05-0.09-0.24-0.40-0.57
Upgrade
EBITDA
-69.17-59.27-45.03-31.79-27.24-17.56
Upgrade
D&A For EBITDA
0.010.010.010.010.010
Upgrade
EBIT
-69.18-59.28-45.03-31.8-27.25-17.56
Upgrade
Revenue as Reported
0.030.030.230.120.080.02
Upgrade
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.